, Singapore
232 views
Photo by Anna Tarazevich via Pexels

GIC makes debut equity move with $126.6M Ascletis Pharma deal

GIC crossed the 5% threshold in HK-listed developer, acquiring 64 million shares.

Singapore’s sovereign wealth fund, GIC Private Limited, has acquired a stake in Ascletis Pharma (01672.HK), according to a disclosure of interests filed with the Hong Kong Stock Exchange (HKEX).

GIC purchased 64.13 million shares at HKD 12.18 per share, for a total consideration of approximately $127.6m (HKD 781.08m).

Following the transaction, GIC holds 6.42% of Ascletis Pharma’s outstanding shares.

The acquisition represents GIC’s initial entry into Ascletis Pharma’s shareholder register.

The disclosure was made under Hong Kong’s Securities and Futures Ordinance, which requires investors to report holdings exceeding 5% of a listed company’s shares.

Ascletis Pharma is listed on the Hong Kong Stock Exchange under the ticker 01672 and is engaged in the research, development, and commercialisation of antiviral and oncology therapies.

GIC Private Limited manages Singapore’s foreign reserves and invests across a broad range of asset classes globally.

($1 = HKD 6.13)
 

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

If you've been wondering whether SBR could work for your company — yes, probably.

A lot of the companies we partner with started as readers. They'd been following our coverage for a while, saw their own customers and competitors in it, and eventually asked the obvious question: could we do something with you? The answer is usually yes. The shape of it depends on what you're trying to do.


The options are broader than most people assume — thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. Some partners use one channel; most use a mix. We figure out the right combination by starting with your brief, not with our rate card.


So if the question has been on your mind, here's the easy way to ask it.

We'll tell you honestly whether we can help, and how. It's a better use of everyone's time.